Decreased NO production in endothelial cells exposed to plasma from ME/CFS patients

Romina Bertinat1, Roberto Villalobos-Labra2, Lidija Hofmann3

  • 1Centro de Microscopía Avanzada, CMA-BIO BIO, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.

Vascular Pharmacology
|January 25, 2022
PubMed

Insights

Plasma from patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) reduces nitric oxide (NO) production in human endothelial cells, indicating a potential role for endothelial nitric oxide synthase (eNOS) in ME/CFS pathophysiology.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Cell Biology

Background:

  • Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease with severe fatigue.
  • Endothelial dysfunction (ED) and altered microRNAs are observed in ME/CFS patients.
  • Inadequate nitric oxide (NO) production by endothelial nitric oxide synthase (eNOS) is a key factor in ED.

Purpose of the Study:

  • To investigate if plasma from ME/CFS patients induces eNOS-related endothelial dysfunction in vitro.
  • To assess the impact of ME/CFS plasma on NO production in human umbilical vein endothelial cells (HUVECs).

Main Methods:

  • HUVECs were cultured with plasma from ME/CFS patients or healthy controls.
  • Nitric oxide (NO) production was measured with and without eNOS activators (tyrosine kinase and G protein-coupled receptors agonists).
  • eNOS phosphorylation at Thr495 was analyzed.

Main Results:

  • HUVECs exposed to ME/CFS plasma exhibited significantly lower NO production compared to those exposed to control plasma, both with and without eNOS activators.
  • GPCR agonist-induced NO production was more impaired than TKR agonist-induced NO production.
  • ME/CFS plasma led to increased inhibitory eNOS phosphorylation at Thr495.

Conclusions:

  • This in vitro study demonstrates that ME/CFS plasma impairs NO production in HUVECs.
  • The findings suggest a novel role for eNOS dysfunction in the pathophysiology of ME/CFS.